Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does REMIFENTANIL Cause Hyperammonaemic encephalopathy? 7 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 7 reports of Hyperammonaemic encephalopathy have been filed in association with REMIFENTANIL (Remifentanil Hydrochloride). This represents 0.3% of all adverse event reports for REMIFENTANIL.

7
Reports of Hyperammonaemic encephalopathy with REMIFENTANIL
0.3%
of all REMIFENTANIL reports
1
Deaths
4
Hospitalizations

How Dangerous Is Hyperammonaemic encephalopathy From REMIFENTANIL?

Of the 7 reports, 1 (14.3%) resulted in death, 4 (57.1%) required hospitalization, and 4 (57.1%) were considered life-threatening.

Is Hyperammonaemic encephalopathy Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for REMIFENTANIL. However, 7 reports have been filed with the FAERS database.

What Other Side Effects Does REMIFENTANIL Cause?

Anaphylactic shock (351) Hypotension (195) Anaphylactic reaction (178) Cardiac arrest (145) Bradycardia (132) Foetal exposure during pregnancy (132) Drug ineffective (112) Off label use (109) Anaesthetic complication neurological (96) Premature baby (91)

What Other Drugs Cause Hyperammonaemic encephalopathy?

VALPROIC ACID (455) FLUOROURACIL (156) VALPROATE (120) DIVALPROEX (119) OXALIPLATIN (107) TOPIRAMATE (101) RISPERIDONE (96) QUETIAPINE (91) LEVETIRACETAM (71) LEUCOVORIN (62)

Which REMIFENTANIL Alternatives Have Lower Hyperammonaemic encephalopathy Risk?

REMIFENTANIL vs REMIMAZOLAM REMIFENTANIL vs REMODULIN REMIFENTANIL vs REPAGLINIDE REMIFENTANIL vs REPOTRECTINIB REMIFENTANIL vs REQUIP

Related Pages

REMIFENTANIL Full Profile All Hyperammonaemic encephalopathy Reports All Drugs Causing Hyperammonaemic encephalopathy REMIFENTANIL Demographics